JP5106402B2 - ナノサイズカロテノイド・シクロデキストリン複合体 - Google Patents
ナノサイズカロテノイド・シクロデキストリン複合体 Download PDFInfo
- Publication number
- JP5106402B2 JP5106402B2 JP2008534755A JP2008534755A JP5106402B2 JP 5106402 B2 JP5106402 B2 JP 5106402B2 JP 2008534755 A JP2008534755 A JP 2008534755A JP 2008534755 A JP2008534755 A JP 2008534755A JP 5106402 B2 JP5106402 B2 JP 5106402B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- carotenoid
- composition
- fish oil
- final blend
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims description 80
- 235000021466 carotenoid Nutrition 0.000 title claims description 79
- 150000001747 carotenoids Chemical class 0.000 title claims description 78
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims description 46
- 239000002105 nanoparticle Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 120
- 238000000034 method Methods 0.000 claims description 39
- 235000021323 fish oil Nutrition 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002002 slurry Substances 0.000 claims description 18
- 235000015872 dietary supplement Nutrition 0.000 claims description 16
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 12
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 12
- 235000013871 bee wax Nutrition 0.000 claims description 11
- 239000012166 beeswax Substances 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 239000001656 lutein Substances 0.000 claims description 7
- 235000012680 lutein Nutrition 0.000 claims description 7
- 229960005375 lutein Drugs 0.000 claims description 7
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 7
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 7
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 7
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 6
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 6
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 6
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 6
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000001751 lycopene Substances 0.000 claims description 6
- 235000012661 lycopene Nutrition 0.000 claims description 6
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 6
- 229960004999 lycopene Drugs 0.000 claims description 6
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 239000001775 zeaxanthin Substances 0.000 claims description 6
- 235000010930 zeaxanthin Nutrition 0.000 claims description 6
- 229940043269 zeaxanthin Drugs 0.000 claims description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 5
- 239000001168 astaxanthin Substances 0.000 claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 5
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 5
- 229940022405 astaxanthin Drugs 0.000 claims description 5
- 229940092738 beeswax Drugs 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
- 229960004853 betadex Drugs 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
- 229960002747 betacarotene Drugs 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
- -1 [beta] -carotene Chemical compound 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims 8
- 235000012041 food component Nutrition 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000007407 health benefit Effects 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940106134 krill oil Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical group CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001579 beta-carotenes Chemical class 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G23/00—Compounds of titanium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Environmental & Geological Engineering (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Manufacturing & Machinery (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Geology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
したがって、本発明は、主に特定の製造技術によって、栄養素、特にカロテノイドのバイオアベイラビリティを改善するための方法及び組成物を提供する。
本発明を記載及び特許請求する際には、次の用語は、下記に示される定義に従って用いられる。
本明細書において用いられる「単回投与量」とは、所望の量のカロテノイドを対象に投与することができる1以上のカプセル投与単位をいう。
本明細書において用いられる場合、便宜のため、複数の部材、構造的要素、組成的要素、及び/又は物質が、共通のリスト中に提示されてもよい。しかしながら、これらリストは、そのリストの各メンバーが別々の唯一のメンバーとして独立に認識されるように解釈されるべきである。したがって、そのようなリストの内の個々のメンバーは、反する表示がない限り、共通の群中にそれらが提示されていることのみに基づいて、同じリストの他のメンバーと事実上等価であると解釈されるべきでない。
発明
本発明は、カロテノイド含有栄養サプリメントを製造するための方法を包含し、それには、カロテノイド−シクロデキストリン複合体を形成することが含まれる。カロテノイドは、種々の健康上の利益を提供することが、栄養学の技術分野においてよく知られている。本発明は、容易に吸収可能なカロテノイド含有栄養サプリメントを製造する方法を提供し、この方法は、容易に実施でき、時間及び費用効果的であり、カロテノイドが高度に安定であり容易に生物学的に利用可能である製品をもたらす。
次の工程にしたがって、安定なカロテノイド含有栄養サプリメントが製造される。
1.5.640kgの水がブレンダーに加えられ、50℃に加熱される。温度は、シクロデキストリンを加える前に確認される。
請求項1の組成物の、対象の皮膚カロテノイドスコア(Skin Carotenoid Scores: SCS)に対する効果を測定するために研究が行なわれた。この研究は、ラマン分光法の使用を含み、プラセボと比較した、実施例1の組成物での補充の18週間にわたる皮膚カロテノイドスコアの変化を評価した。
Claims (28)
- カロテノイド含有栄養サプリメントを製造する方法であって、
a)所定量のシクロデキストリンと水とを混合して、水/シクロデキストリンスラリーを50℃で形成し、
b)所定量の少なくとも一種のカロテノイドを当該水/シクロデキストリンスラリーに混ぜて、シクロデキストリン・カロテノイド複合体を含むプレブレンド組成物を形成し、
c)当該プレブレンド組成物上で真空引きをし、当該プレブレンド組成物を最小限1時間徹底的に混合し、
d)当該乾燥されていないプレブレンド組成物と追加の栄養成分とを、約40℃〜45℃の温度で真空下で混合することによって最終ブレンドを形成し、
e)当該最終ブレンドを真空中で粉砕し、
f)当該粉砕された最終ブレンドを被包化する
ことを含む方法。 - シクロデキストリンがγ−シクロデキストリンである、請求項1に記載の方法。
- シクロデキストリンが、γ−シクロデキストリンとβ−シクロデキストリンとの組合せである、請求項1に記載の方法。
- 少なくとも一種のカロテノイドが、アスタキサンチン、リコピン、ゼアキサンチン、β−カロテン、ルテイン及びその混合物からなる群から選択される、請求項1に記載の方法。
- 追加の栄養成分が、魚油、蜜蝋、ビタミンA、ビタミンE、D−リモネン及びその混合物からなる群から選択される、請求項1に記載の方法。
- 追加の栄養成分が魚油を含む、請求項5に記載の方法。
- 魚油が、前記最終ブレンドの70重量%〜90重量%を構成する、請求項6に記載の方法。
- 魚油が、前記最終ブレンドの75重量%〜85重量%を構成する、請求項7に記載の方法。
- 前記粉砕された最終ブレンドが、ソフトゼラチンカプセル中に被包化される、請求項1に記載の方法。
- カロテノイド含有栄養サプリメントを製造する方法であって、
a)ブレンド装置中で所定量の水を50℃に加熱し、
b)所定量のシクロデキストリンと水とを混合して、水/シクロデキストリンスラリーを形成し、
c)所定量の少なくとも一種のカロテノイドを当該水/シクロデキストリンスラリーに混ぜて、シクロデキストリン・カロテノイド複合体を含むプレブレンド組成物を形成し、
d)当該プレブレンド組成物上で真空引きをし、当該プレブレンド組成物を最小限1時間徹底的に混合し、
e)別の混合容器中で、所定量の魚油を40℃〜45℃に温め、
f)当該乾燥されていないプレブレンド組成物と当該魚油とを、約40℃〜45℃の温度で真空下で混合することによって最終ブレンドを形成し、
g)場合により、追加の栄養成分を当該最終ブレンドに混ぜ、
h)最終ブレンド混合物を25℃〜28℃に冷却し、
i)当該最終ブレンドを真空中で粉砕して、粒子径を低下させ、
j)当該粉砕された最終ブレンドを被包化する
ことを含む方法。 - シクロデキストリンがγ−シクロデキストリンである、請求項10に記載の方法。
- シクロデキストリンが、γ−シクロデキストリンとβ−シクロデキストリンとの組合せである、請求項10に記載の方法。
- 少なくとも一種のカロテノイドが、アスタキサンチン、リコピン、ゼアキサンチン、β−カロテン、ルテイン及びその混合物からなる群から選択される、請求項10に記載の方法。
- 追加の栄養成分が、蜜蝋、ビタミンA、ビタミンE、D−リモネン及びその混合物からなる群から選択される、請求項10に記載の方法。
- 少なくとも一種のカロテノイド;
シクロデキストリン;及び
魚油
を含む、カロテノイド含有組成物であって、当該魚油が、当該組成物の70重量%〜90重量%を構成する組成物。 - シクロデキストリンがγ−シクロデキストリンである、請求項15に記載の組成物。
- シクロデキストリンが、γ−シクロデキストリンとβ−シクロデキストリンとの組合せである、請求項15に記載の組成物。
- 少なくとも一種のカロテノイドが、アスタキサンチン、リコピン、ゼアキサンチン、β−カロテン、ルテイン及びその混合物からなる群から選択される、請求項15に記載の組成物。
- さらに、蜜蝋、ビタミンA、ビタミンE、D−リモネン及びその混合物からなる群から選択される追加の栄養成分を含む、請求項15に記載の組成物。
- 前記魚油が組成物の75重量%〜85重量%を構成し、存在する、請求項15に記載の組成物。
- 前記少なくとも一種のカロテノイドが、シクロデキストリンと複合体化している、請求項15に記載の組成物。
- カロテノイドのバイオアベイラビリティを向上させる方法であって、
それを必要とする対象に、カロテノイドと、シクロデキストリン及び魚油の組み合わせとを共投与することを含む方法。 - カロテノイドとシクロデキストリンとが一緒に複合体化している、請求項22に記載の方法。
- シクロデキストリンがγ−シクロデキストリンである、請求項22に記載の方法。
- シクロデキストリンが、γ−シクロデキストリンとβ−シクロデキストリンとの組合せである、請求項22に記載の方法。
- カロテノイドが、アスタキサンチン、リコピン、ゼアキサンチン、β−カロテン、ルテイン及びその混合物からなる群から選択される、請求項22に記載の方法。
- 追加の栄養成分が共投与され、当該追加の栄養成分が、蜜蝋、ビタミンA、ビタミンE、D−リモネン及びその混合物からなる群から選択される、請求項22に記載の方法。
- カロテノイド、シクロデキストリン及び魚油が、単回投与形態で投与される、請求項22に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72405105P | 2005-10-05 | 2005-10-05 | |
US60/724,051 | 2005-10-05 | ||
US11/538,766 | 2006-10-04 | ||
US11/538,766 US7781572B2 (en) | 2005-10-05 | 2006-10-04 | Nanosized carotenoid cyclodextrin complexes |
PCT/US2006/039383 WO2007044659A2 (en) | 2005-10-05 | 2006-10-05 | Nanosized carotenoid cyclodextrin complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009524576A JP2009524576A (ja) | 2009-07-02 |
JP5106402B2 true JP5106402B2 (ja) | 2012-12-26 |
Family
ID=37943453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008534755A Active JP5106402B2 (ja) | 2005-10-05 | 2006-10-05 | ナノサイズカロテノイド・シクロデキストリン複合体 |
Country Status (7)
Country | Link |
---|---|
US (5) | US7781572B2 (ja) |
EP (1) | EP1931361A4 (ja) |
JP (1) | JP5106402B2 (ja) |
KR (1) | KR101255874B1 (ja) |
CN (1) | CN101505596B (ja) |
TW (2) | TWI514970B (ja) |
WO (1) | WO2007044659A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7781572B2 (en) * | 2005-10-05 | 2010-08-24 | Nse Products, Inc. | Nanosized carotenoid cyclodextrin complexes |
ES2317786B1 (es) * | 2007-07-31 | 2010-02-16 | Consejo Superior De Investigaciones Cientificas | Agregado o complejo molecular carotenoide soluble, procedimiento de obtencion y sus aplicaciones. |
NO20081487L (no) | 2008-03-27 | 2009-09-28 | Smartfish As | Helsefremmende drikk |
GB0817701D0 (en) * | 2008-09-26 | 2008-11-05 | Omegatri As | Krill oil powder and krill oil tablets |
US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
US20130011469A1 (en) | 2009-07-23 | 2013-01-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Krill oil and carotenoid composition, associated method and delivery system |
US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
US20110144200A1 (en) * | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
US8410079B2 (en) * | 2010-08-06 | 2013-04-02 | Island Kinetics | Chirally correct retinal cyclodextrin hemiacetals for clarifying skin complexion |
DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
AR095937A1 (es) | 2013-04-05 | 2015-11-25 | Acraf | Potenciador de la solubilidad en agua a base de glucógeno |
KR101468308B1 (ko) | 2013-05-31 | 2014-12-03 | 명지대학교 산학협력단 | 카로티노이드 나노입자의 제조방법 |
JP2015159801A (ja) * | 2014-02-28 | 2015-09-07 | サンデン商事株式会社 | γ−トコトリエノールにより酸化防止されたクリルオイルを含むサプリメント |
JP6299689B2 (ja) * | 2014-07-24 | 2018-03-28 | 三生医薬株式会社 | 生体吸収促進剤含有組成物 |
CN104784059A (zh) * | 2015-03-14 | 2015-07-22 | 吉林中粮生化有限公司 | 一种类胡萝卜素包合物和聚谷氨酸组合物及其用途 |
CN107158400A (zh) * | 2017-07-10 | 2017-09-15 | 北京素维生物科技有限公司 | 眼睛营养强化剂溶液组合物及其制备方法 |
WO2019046660A1 (en) | 2017-08-30 | 2019-03-07 | Shawn Talbott | NUTRITIONAL COMPONENTS AFFECTING THE BALANCE OF THE INTESTINE-BRAIN AXIS AND MENTAL WELFARE |
MX2022002767A (es) | 2019-09-04 | 2022-07-04 | Amare Global | Complementos nutricionales y métodos de complementación nutricional que afectan al humor y a la concentración en niños. |
US11529387B2 (en) | 2019-09-04 | 2022-12-20 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting global mood state |
WO2021046450A1 (en) | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of supplementation affecting the endocannabinoid system |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834445A (en) | 1989-08-11 | 1998-11-10 | Sikorski; Christopher | Process for preparing decolorized carotenoid-cyclodextrin complexes |
IT1243192B (it) * | 1990-08-09 | 1994-05-24 | Staroil Ltd | Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine |
US5221735A (en) | 1991-02-25 | 1993-06-22 | Hoffmann-La Roche Inc. | Cyclodextrin-polyene inclusion complexes |
US5321014A (en) | 1991-06-28 | 1994-06-14 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells |
WO1996040262A2 (en) | 1995-06-07 | 1996-12-19 | The Procter & Gamble Company | Process for preparing encapsulated water soluble beta-carotene |
IL121112A (en) * | 1997-06-19 | 2005-11-20 | Lycored Natural Prod Ind Ltd | Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
DE19941769A1 (de) | 1999-09-02 | 2001-03-08 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Biotin und/oder Biotinderivaten und Cyclodextrinen und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
DE10035513A1 (de) | 2000-07-21 | 2002-01-31 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
US6884885B2 (en) | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
US6695453B2 (en) * | 2001-02-09 | 2004-02-24 | Avery Dennison Corporation | Rear projection screens and light filters with conformable coatings and methods of making the same |
FR2823207B1 (fr) | 2001-04-10 | 2004-12-03 | Pf Medicament | Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies |
ITMI20012749A1 (it) | 2001-12-21 | 2003-06-21 | Chiesi Farma Spa | Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut |
JP2005528383A (ja) * | 2002-04-10 | 2005-09-22 | ミラー,フレッド,エイチ. | 多重相・複数コンパートメントカプセルシステム |
EP1511811A2 (en) * | 2002-05-30 | 2005-03-09 | Phares Pharmaceutical Research N.V. | Oil-soluble pigment compositions |
WO2004005353A1 (en) | 2002-07-04 | 2004-01-15 | Poltec As | Complexes of cyclodextrins and carotenoids |
US20040109920A1 (en) * | 2002-12-04 | 2004-06-10 | Bioactives Llc | Coated carotenoid cyclodextrin complexes |
WO2005075613A1 (en) * | 2004-02-06 | 2005-08-18 | Adrien Beaudoin | Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof |
CN1917772A (zh) | 2004-02-23 | 2007-02-21 | 得克萨斯A&M大学系统 | 抗氧化组合物及其使用方法 |
US8067045B2 (en) * | 2005-03-03 | 2011-11-29 | Pharmanex, Llc | Nutritional formulations and associated methods |
US7781572B2 (en) * | 2005-10-05 | 2010-08-24 | Nse Products, Inc. | Nanosized carotenoid cyclodextrin complexes |
-
2006
- 2006-10-04 US US11/538,766 patent/US7781572B2/en active Active
- 2006-10-05 KR KR1020087008961A patent/KR101255874B1/ko active IP Right Grant
- 2006-10-05 TW TW103125072A patent/TWI514970B/zh active
- 2006-10-05 JP JP2008534755A patent/JP5106402B2/ja active Active
- 2006-10-05 TW TW095137067A patent/TWI462740B/zh active
- 2006-10-05 EP EP06836231A patent/EP1931361A4/en not_active Withdrawn
- 2006-10-05 WO PCT/US2006/039383 patent/WO2007044659A2/en active Application Filing
- 2006-10-05 CN CN2006800372474A patent/CN101505596B/zh active Active
-
2010
- 2010-05-20 US US12/784,387 patent/US20110129562A1/en not_active Abandoned
-
2016
- 2016-03-01 US US15/058,046 patent/US20170021035A1/en not_active Abandoned
-
2018
- 2018-04-16 US US15/954,464 patent/US20190111020A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/216,506 patent/US20210322371A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190111020A1 (en) | 2019-04-18 |
EP1931361A4 (en) | 2012-01-25 |
TW201440665A (zh) | 2014-11-01 |
WO2007044659A2 (en) | 2007-04-19 |
US20070191307A1 (en) | 2007-08-16 |
US20170021035A1 (en) | 2017-01-26 |
WO2007044659A3 (en) | 2009-04-30 |
US7781572B2 (en) | 2010-08-24 |
EP1931361A2 (en) | 2008-06-18 |
TWI514970B (zh) | 2016-01-01 |
TWI462740B (zh) | 2014-12-01 |
US20110129562A1 (en) | 2011-06-02 |
KR101255874B1 (ko) | 2013-04-17 |
TW200800229A (en) | 2008-01-01 |
KR20080055920A (ko) | 2008-06-19 |
JP2009524576A (ja) | 2009-07-02 |
CN101505596B (zh) | 2012-07-18 |
CN101505596A (zh) | 2009-08-12 |
US20210322371A1 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5106402B2 (ja) | ナノサイズカロテノイド・シクロデキストリン複合体 | |
JP5147239B2 (ja) | コエンザイムq10含有乳化組成物 | |
CN1741748A (zh) | 粉末状植物甾醇配方 | |
EP0324762A1 (en) | A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it | |
JP2006306825A (ja) | 安定化α−リポ酸組成物及びその利用 | |
WO2005097091A1 (ja) | 還元型補酵素q10およびカロチノイド類を含有した組成物 | |
KR20200132584A (ko) | 안정화된 아스타잔틴 나노입자와 그 제조방법 | |
JP2014131961A (ja) | 動物用栄養組成物 | |
TW201924541A (zh) | 含有飲食品用藻類組合物及其製造方法 | |
JP2012131768A (ja) | 改善された吸収性及びバイオアベイラビリティを有するカロテノイド組成物及びその適用 | |
JP2003304845A (ja) | 飲料または食品 | |
JP2019135217A (ja) | 粉状組成物、粉状組成物の製造方法、ドライアイ改善剤、肌質改善剤、飲食物、化粧品、及びペットフード | |
WO2021178291A1 (en) | Undenatured type ii collagen in food and beverage applications and uses thereof | |
JP2016067300A (ja) | 飲料組成物及び飲料組成物の製造方法 | |
JP6464745B2 (ja) | 生理活性物質の担持力を向上させたナノ粒子の製造方法 | |
JP2004357507A (ja) | ペット用サプリメント | |
JP2018009038A (ja) | 経口用組成物 | |
JP6241631B2 (ja) | 経口用組成物 | |
JP2016124804A (ja) | 天然物由来成分を基材とするナノ粒子の製造方法 | |
JP6443009B2 (ja) | 生理活性物質の担持力を向上させたナノ粒子の製造方法 | |
JP2006050933A (ja) | クロレラ栄養補助食品 | |
JP2012077087A (ja) | 安定なアスタキサンチンとγ−シクロデキストリンとの包接化合物、並びにそれを含む飲食物、飼料及び医薬品 | |
JP6010482B2 (ja) | 経口用組成物 | |
JP2019142923A (ja) | 経口用組成物 | |
CN1747716A (zh) | 包含多个具有限定粒径的颗粒或附聚物的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090729 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120810 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120817 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121002 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5106402 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151012 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |